Hillary A Keenan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9179026/publications.pdf

Version: 2024-02-01

304368 264894 2,161 43 22 42 h-index citations g-index papers 43 43 43 3231 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108134.	1.2	5
2	Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I. Archives of Disease in Childhood, 2021, 106, 674-679.	1.0	13
3	High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes. Diabetes Care, 2020, 43, 178-186.	4.3	39
4	Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Science Translational Medicine, 2019, 11 ,.	5.8	62
5	Estimating GFR by Serum Creatinine, Cystatin C, and \hat{I}^2 2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. Kidney International Reports, 2019, 4, 786-796.	0.4	12
6	Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy. Diabetes Care, 2019, 42, 1263-1273.	4. 3	72
7	Characterization of periodontitis in people with type 1 diabetes of 50 years or longer duration. Journal of Periodontology, 2019, 90, 565-575.	1.7	21
8	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107324.	1.2	21
9	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 575-583.	2.2	15
10	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2019, 42, 273-280.	4.3	16
11	Residual \hat{l}^2 cell function and monogenic variants in long-duration type 1 diabetes patients. Journal of Clinical Investigation, 2019, 129, 3252-3263.	3.9	62
12	Meta-genome-wide association studies identify a locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1 diabetes. Diabetologia, 2018, 61, 1098-1111.	2.9	26
13	Differential Association of Microvascular Attributions With Cardiovascular Disease in Patients With Long Duration of Type 1 Diabetes. Diabetes Care, 2018, 41, 815-822.	4.3	23
14	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 831-839.	4. 3	13
15	Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 92-101.	1.1	42
16	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	4.3	17
17	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 2570-2578.	4.3	37
18	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2018, 32, 660-664.	1.2	22

#	Article	IF	Citations
19	Cognitive Function Deficits Associated With Long-Duration Type 1 Diabetes and Vascular Complications. Diabetes Care, 2018, 41, 1749-1756.	4.3	46
20	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight, $2018,3,.$	2.3	38
21	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. PLoS ONE, 2018, 13, e0196647.	1.1	13
22	Bone health in subjects with type 1 diabetes for more than 50Âyears. Acta Diabetologica, 2017, 54, 479-488.	1.2	38
23	Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nature Medicine, 2017, 23, 753-762.	15.2	337
24	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1318-1324.	1.2	37
25	Association of Glycemic Control With Reduced Risk for Large-Vessel Disease After More Than 50 Years of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3704-3711.	1.8	32
26	High density lipoprotein modulates osteocalcin expression in circulating monocytes: a potential protective mechanism for cardiovascular disease in type 1 diabetes. Cardiovascular Diabetology, 2017, 16, 116.	2.7	13
27	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 298-307.	2.4	25
28	Bone Microarchitecture in Type 1 Diabetes: It Is Complicated. Current Osteoporosis Reports, 2016, 14, 351-358.	1.5	24
29	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovascular Diabetology, 2016, 15, 14.	2.7	29
30	Relation of Body Circumferences to Cardiometabolic Disease in Overweight-Obese Subjects. American Journal of Cardiology, 2016, 118, 822-827.	0.7	20
31	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. Diabetes Care, 2016, 39, e67-e68.	4.3	19
32	Preserved DNA Damage Checkpoint Pathway Protects against Complications in Long-Standing Type 1 Diabetes. Cell Metabolism, 2015, 22, 239-252.	7.2	40
33	Cardiovascular Disease Protection in Long-Duration Type 1 Diabetes and Sex Differences. Diabetes Care, 2015, 38, e73-e74.	4.3	13
34	Improvement of Insulin Sensitivity by Isoenergy High Carbohydrate Traditional Asian Diet: A Randomized Controlled Pilot Feasibility Study. PLoS ONE, 2014, 9, e106851.	1.1	17
35	Characterization of Circulating and Endothelial Progenitor Cells in Patients With Extreme-Duration Type 1 Diabetes. Diabetes Care, 2014, 37, 2193-2201.	4.3	42
36	Bridging the gap - planning Lifestyle Medicine fellowship curricula: A cross sectional study. BMC Medical Education, 2014, 14, 1045.	1.0	14

#	Article	IF	CITATION
37	Do Erectile Dysfunction and Cardiovascular Disease Have the Same Mechanism?. European Urology, 2014, 65, 979-980.	0.9	10
38	Sexual Dysfunction as a Marker of Cardiovascular Disease in Males With 50 or More Years of Type 1 Diabetes. Diabetes Care, 2013, 36, 3222-3226.	4.3	26
39	Characterization of Factors Affecting Attainment of Glycemic Control in Asian Americans With Diabetes in a Culturally Specific Program. The Diabetes Educator, 2013, 39, 468-477.	2.6	7
40	Response to Comment on: Sun et al. Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration: The Joslin 50-Year Medalist Study. Diabetes Care 2011;34:968–974. Diabetes Care, 2011, 34, e149-e149.	4.3	0
41	Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration. Diabetes Care, 2011, 34, 968-974.	4.3	213
42	Residual Insulin Production and Pancreatic \hat{l}^2 -Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study. Diabetes, 2010, 59, 2846-2853.	0.3	422
43	Clinical Factors Associated With Resistance to Microvascular Complications in Diabetic Patients of Extreme Disease Duration. Diabetes Care, 2007, 30, 1995-1997.	4.3	168